{"title":"Panitumumab (Vectibix): risk of necrotising fasciitis","public_updated_at":"2014-12-11T14:33:33Z","details":{"metadata":{"therapeutic_area":["cancer"],"first_published_at":"2012-09-25T00:00:00Z","bulk_published":true,"document_type":"drug_safety_update"},"change_history":[],"body":[{"content_type":"text/html","content":"<p>Article date: September 2012 <br />\nPanitumumab (Vectibix) is an epidermal growth factor receptor inhibitor used as monotherapy and in combination with oxaliplatin- and irinotecan-based chemotherapy to treat patients with non-mutated (wild-type) KRAS metastatic colorectal cancer.  </p>\n\n<p>Severe skin reactions with panitumumab use are known to be very common (in at least 1 out of 10 individuals) and may be followed by life-threatening and fatal infectious complications including sepsis and cellulitis. In addition, five cases of necrotising fasciitis, three of which were fatal, have now been reported in patients treated with panitumumab in combination with chemotherapy. The cases occurred both in clinical trials and the post-marketing setting.  </p>\n\n<p>The main symptoms of necrotising fasciitis are: intense and severe pain which may seem out of proportion to any external signs of infection on the skin; fever, diarrhoea and vomiting and eventual unconsciousness; skin typically becoming a dark violet colour, with the formation of blisters and death of the tissue underneath.  </p>\n\n<p>Patients who have severe skin reactions or who develop worsening skin reactions whilst receiving panitumumab should be monitored for the development of inflammatory or infectious sequelae. If such complications develop, withhold or discontinue panitumumab, and initiate appropriate therapy promptly.  </p>\n\n<p>Further information:  </p>\n\n<p><a rel=\"external\" href=\"https://assets.digital.cabinet-office.gov.uk/media/547307f3e5274a130100003a/con175480.pdf\">Letter sent to healthcare professionals in August 2012</a>  </p>\n\n<p>BNF section 6.1: <a rel=\"external\" href=\"http://www.medicinescomplete.com/mc/bnf/current/4676.htm\">Cytotoxic drugs</a>  </p>\n\n<p>Article citation: Drug Safety Update September 2012, vol 6, issue 2: S1</p>\n"},{"content_type":"text/govspeak","content":"Article date: September 2012   \r\nPanitumumab (Vectibix) is an epidermal growth factor receptor inhibitor used as monotherapy and in combination with oxaliplatin- and irinotecan-based chemotherapy to treat patients with non-mutated (wild-type) KRAS metastatic colorectal cancer.  \r\n  \r\nSevere skin reactions with panitumumab use are known to be very common (in at least 1 out of 10 individuals) and may be followed by life-threatening and fatal infectious complications including sepsis and cellulitis. In addition, five cases of necrotising fasciitis, three of which were fatal, have now been reported in patients treated with panitumumab in combination with chemotherapy. The cases occurred both in clinical trials and the post-marketing setting.  \r\n  \r\nThe main symptoms of necrotising fasciitis are: intense and severe pain which may seem out of proportion to any external signs of infection on the skin; fever, diarrhoea and vomiting and eventual unconsciousness; skin typically becoming a dark violet colour, with the formation of blisters and death of the tissue underneath.  \r\n  \r\nPatients who have severe skin reactions or who develop worsening skin reactions whilst receiving panitumumab should be monitored for the development of inflammatory or infectious sequelae. If such complications develop, withhold or discontinue panitumumab, and initiate appropriate therapy promptly.  \r\n  \r\nFurther information:  \r\n  \r\n[InlineAttachment:con175480.pdf]  \r\n  \r\nBNF section 6.1: [Cytotoxic drugs](http://www.medicinescomplete.com/mc/bnf/current/4676.htm)  \r\n  \r\nArticle citation: Drug Safety Update September 2012, vol 6, issue 2: S1\r\n"}],"max_cache_time":10,"temporary_update_type":false,"attachments":[{"content_id":"ea2ebfb0-8d19-4c73-83a9-c1f49a4c5838","title":"Letter sent to healthcare professionals in August 2012","url":"https://assets.digital.cabinet-office.gov.uk/media/547307f3e5274a130100003a/con175480.pdf","updated_at":"2014-11-24T10:26:59Z","created_at":"2014-11-24T10:26:59Z","content_type":"application/pdf"}]},"routes":[{"path":"/drug-safety-update/panitumumab-vectibix-risk-of-necrotising-fasciitis","type":"exact"}],"redirects":[],"publishing_app":"specialist-publisher","rendering_app":"government-frontend","need_ids":[],"phase":"live","analytics_identifier":null,"document_type":"drug_safety_update","schema_name":"specialist_document","first_published_at":"2016-02-29T09:24:10Z","base_path":"/drug-safety-update/panitumumab-vectibix-risk-of-necrotising-fasciitis","description":"Five cases of necrotising fasciitis have been reported in patients treated with panitumumab in combination with chemotherapy.","content_id":"5bf55d3d-f483-469d-8ec2-de97be4f9fbf","locale":"en","expanded_links":{"organisations":[{"analytics_identifier":"EA63","api_path":"/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency","base_path":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","description":null,"document_type":"organisation","locale":"en","public_updated_at":"2015-06-29T14:33:29Z","schema_name":"placeholder","title":"Medicines and Healthcare products Regulatory Agency","withdrawn":false,"details":{"brand":"department-of-health","logo":{"formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","crest":"single-identity"}},"links":{}}],"finder":[{"analytics_identifier":null,"api_path":"/api/content/drug-safety-update","base_path":"/drug-safety-update","content_id":"602be505-4cf4-4f8c-8bfc-7bc4b63a7f47","description":"Find drug safety updates issued by MHRA","document_type":"finder","locale":"en","public_updated_at":"2017-03-30T10:34:00Z","schema_name":"finder","title":"Drug Safety Update","withdrawn":false,"details":{"document_noun":"update","filter":{"document_type":"drug_safety_update"},"format_name":"Drug Safety Update","show_summaries":true,"facets":[{"key":"therapeutic_area","name":"Therapeutic area","type":"text","preposition":"about","display_as_result_metadata":true,"filterable":true,"allowed_values":[{"label":"Anaesthesia and intensive care","value":"anaesthesia-intensive-care"},{"label":"Cancer","value":"cancer"},{"label":"Cardiovascular disease and lipidology","value":"cardiovascular-disease-lipidology"},{"label":"Dentistry","value":"dentistry"},{"label":"Dermatology","value":"dermatology"},{"label":"Ear, nose and throat","value":"ear-nose-throat"},{"label":"Endocrinology, diabetology and metabolism","value":"endocrinology-diabetology-metabolism"},{"label":"GI, hepatology and pancreatic disorders","value":"gi-hepatology-pancreatic-disorders"},{"label":"Haematology","value":"haematology"},{"label":"Immunology and vaccination","value":"immunology-vaccination"},{"label":"Immunosuppression and transplantation","value":"immunosuppression-transplantation"},{"label":"Infectious disease","value":"infectious-disease"},{"label":"Neurology","value":"neurology"},{"label":"Nutrition and dietetics","value":"nutrition-dietetics"},{"label":"Obstetrics, gynaecology and fertility","value":"obstetrics-gynaecology-fertility"},{"label":"Ophthalmology","value":"ophthalmology"},{"label":"Paediatrics and neonatology","value":"paediatrics-neonatology"},{"label":"Pain management and palliation","value":"pain-management-palliation"},{"label":"Psychiatry","value":"psychiatry"},{"label":"Radiology and imaging","value":"radiology-imaging"},{"label":"Respiratory disease and allergy","value":"respiratory-disease-allergy"},{"label":"Rheumatology","value":"rheumatology"},{"label":"Urology and nephrology","value":"urology-nephrology"}]},{"key":"first_published_at","name":"Published","short_name":"Published","type":"date","preposition":"published","display_as_result_metadata":true,"filterable":true}],"default_documents_per_page":50},"links":{}}],"available_translations":[{"title":"Panitumumab (Vectibix): risk of necrotising fasciitis","public_updated_at":"2014-12-11T14:33:33Z","analytics_identifier":null,"document_type":"drug_safety_update","schema_name":"specialist_document","base_path":"/drug-safety-update/panitumumab-vectibix-risk-of-necrotising-fasciitis","description":"Five cases of necrotising fasciitis have been reported in patients treated with panitumumab in combination with chemotherapy.","api_path":"/api/content/drug-safety-update/panitumumab-vectibix-risk-of-necrotising-fasciitis","withdrawn":false,"content_id":"5bf55d3d-f483-469d-8ec2-de97be4f9fbf","locale":"en"}]},"format":"specialist_document","navigation_document_supertype":"other","user_journey_document_supertype":"thing","email_document_supertype":"other","government_document_supertype":"other","payload_version":0}